The Japanese Patent Office (JPO) has granted a new drug substance patent for Swedish biopharma company BioArctic’s monoclonal antibody (mAb), BAN0805, to treat Parkinson’s disease.
The patent for the antibody will expire in 2041, with the potential for extension until 2046.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
BAN0805 selectively attaches to and removes oligomers, which are pathological aggregated forms, as well as protofibrils. It does not impact the alpha-synuclein’s physiological monomer form.
The company plans to advance the mAb as a treatment that stops or decelerates Parkinson’s disease progression.
Findings from a Phase I clinical trial of BAN0805 supported the continued development of BAN0805 in a Phase II study, dosing once a month.
BioArctic CEO Gunilla Osswald stated: “I am delighted to announce that the Japanese Patent Office is granting a new drug substance patent for BAN0805, securing a valuable and extensive period of patent protection.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“This patent further strengthens BioArctic’s patent portfolio and supports our important efforts to develop potential treatments in Parkinson’s disease and other synucleinopathies.”
The company was established in 2003 on the basis of research from Uppsala University in Sweden.
It develops disease-modifying therapies for neurodegenerative ailments such as Alzheimer’s, Parkinson’s and amyotrophic lateral sclerosis.
BioArctic also has a strategic partnership in place with Eisai for Alzheimer’s disease.
